Agilent stock maintains Buy rating at TD Cowen on strong outlook

Agilent (NYSE: A) reported strong Q3 FY25 results, exceeding revenue forecasts with $1.74 billion and achieving 6.1% organic growth, significantly above consensus, while meeting EPS expectations. TD Cowen reiterated its Buy rating and $150 price target, citing continued positive momentum into FY26 for its pharmaceutical and Chemical & Applied segments, and an under-leveraged balance sheet suggesting M&A potential, despite some Q3 margin pressure. This performance and positive outlook from key analysts, including Bernstein, underscore Agilent's positive trajectory, though KeyBanc maintained a Sector Weight rating.

Analysis

Agilent Technologies (A) demonstrated strong fiscal third-quarter performance, beating revenue forecasts with $1.74 billion against an anticipated $1.67 billion and achieving organic growth of 6.1%, significantly outpacing the 3.6% consensus. While earnings per share met expectations at $1.37, the company experienced margin pressure in the quarter, though analysts at TD Cowen anticipate future margin expansion. Key growth drivers include the pharmaceutical segment, noted for its strength in small molecule products and nucleic acid sample preparation, and the Chemical & Applied segment, which is benefiting from mass spectrometry upgrades and semiconductor industry demand. The company's strategic framework, "Project Ignite," is viewed by some analysts as an underappreciated catalyst. Furthermore, Agilent's under-leveraged balance sheet, characterized by a moderate 0.56 debt-to-equity ratio and a 2.25 current ratio, supports management's stated focus on mergers and acquisitions as a potential growth lever. Analyst sentiment is positive but mixed; TD Cowen reiterated a Buy rating with a $150 price target, while KeyBanc holds a Sector Weight rating and Bernstein SocGen a Market Perform with a $125 target, suggesting a divergence in valuation assessment despite the strong operational results.

Key Decisions for Investors

• Investors should consider the strong top-line momentum and 6.1% organic growth beat as a primary bullish signal, supported by specific strength in the pharma and chemical segments.
• Monitor upcoming quarterly results closely for evidence of the projected margin expansion, as the Q3 margin shortfall represents a key risk that could offset the positive revenue narrative.
• The under-leveraged balance sheet and management's focus on M&A position the company for a potential near-term catalyst, warranting attention on any deal-related announcements.
• Given the split analyst ratings and a current price ($128.48) that is above some price targets ($125) and fair value estimates, it is prudent to weigh the strong operational performance against potential valuation headwinds.